<DOC>
	<DOCNO>NCT01140672</DOCNO>
	<brief_summary>The goal study evaluate safety tolerability multiple ascend dos PF-04634817 administer orally healthy adult subject . In additional , plasma urinary pharmacokinetics multiple ascend dos PF-04634817 administer orally healthy adult subject evaluate . Finally , effect multiple dose PF-04634817 circulate monocyte explore .</brief_summary>
	<brief_title>A Multiple Dose Study To Determine Safety , Tolerability , Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female ( nonchildbearing potential ) subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication ; Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day ; Nursing female ; Females childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>multiple dosing</keyword>
	<keyword>Diabetic Nephropathies</keyword>
</DOC>